Literature DB >> 34970669

Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome.

Simon Alesi1, Carolyn Ee2, Lisa J Moran1, Vibhuti Rao2, Aya Mousa1.   

Abstract

Polycystic ovary syndrome (PCOS) affects 1 in 5 women of reproductive age, and is characterized by menstrual irregularities, clinical or biochemical hyperandrogenism, and the presence of polycystic ovary morphology. One of the recommended treatment strategies in the international evidence-based guidelines is lifestyle modification, which includes diet and exercise, with the aim of improving a range of health outcomes. The incurable nature of PCOS reinforces the importance of developing novel and innovative symptomatic relief strategies, which are currently the only available approaches for improving quality of life for these women. Women with PCOS tend to be nutrient deficient in many common vitamins and minerals, thought to be associated with the psychological (depression, anxiety, etc.) and physiological (insulin resistance, diabetes, infertility, etc.) sequelae of the condition. Nutrient supplementation and the integration of complementary medicine as adjuncts to traditional lifestyle-based therapies in PCOS could therefore provide additional benefits to these women. In this review, we synthesize the evidence regarding nutrient supplementation and complementary therapies in PCOS, predominantly from randomized controlled trials, systematic reviews, and meta-analyses, to provide an overview of the state of knowledge in this field. The evidence to date suggests that specific vitamins (B-12, inositols, folate, vitamins D, E, and K), vitamin-like nutrients (bioflavonoids and α-lipoic acid), minerals (calcium, zinc, selenium, and chromium picolinate), and other formulations (melatonin, ω-3 fatty acids, probiotics, and cinnamon), as well as some complementary approaches such as acupuncture and yoga may be beneficial in PCOS. However, there remain areas of uncertainty and key limitations in the literature that must be overcome before these therapies can be integrated into routine clinical practice.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.

Entities:  

Keywords:  PCOS; complementary medicine; diet; minerals; nutraceutical; nutrition; polycystic ovary syndrome; review; supplementation; vitamins

Mesh:

Substances:

Year:  2022        PMID: 34970669      PMCID: PMC9340985          DOI: 10.1093/advances/nmab141

Source DB:  PubMed          Journal:  Adv Nutr        ISSN: 2161-8313            Impact factor:   11.567


  189 in total

1.  Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical trial.

Authors:  Leila Amini; Faraz Mojab; Shayesteh Jahanfar; Mahdi Sepidarkish; Zahra Raoofi; Arezoo Maleki-Hajiagha
Journal:  Complement Ther Med       Date:  2019-11-13       Impact factor: 2.446

2.  Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials.

Authors:  Fahimeh Haghighatdoost; Mitra Hariri
Journal:  Eur J Pharmacol       Date:  2019-01-08       Impact factor: 4.432

3.  Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.

Authors:  Zi-Jiang Chen; Han Zhao; Lin He; Yuhua Shi; Yingying Qin; Yongyong Shi; Zhiqiang Li; Li You; Junli Zhao; Jiayin Liu; Xiaoyan Liang; Xiaoming Zhao; Junzhao Zhao; Yingpu Sun; Bo Zhang; Hong Jiang; Dongni Zhao; Yuehong Bian; Xuan Gao; Ling Geng; Yiran Li; Dongyi Zhu; Xiuqin Sun; Jin-E Xu; Cuifang Hao; Chun-E Ren; Yajie Zhang; Shiling Chen; Wei Zhang; Aijun Yang; Junhao Yan; Yuan Li; Jinlong Ma; Yueran Zhao
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

4.  The mediating role of the parathyroid gland in the effect of low calcium intake on blood pressure in the rat.

Authors:  J M Belizán; J Villar; S Self; O Pineda; I González; E Sainz
Journal:  Arch Latinoam Nutr       Date:  1984-12

5.  Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.

Authors:  Manuel Luque-Ramírez; Francisco Alvarez-Blasco; José I Botella-Carretero; Raul Sanchón; José L San Millán; Héctor F Escobar-Morreale
Journal:  Diabetes Care       Date:  2007-05-29       Impact factor: 19.112

6.  Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.

Authors:  Zatollah Asemi; Maryam Karamali; Ahmad Esmaillzadeh
Journal:  Mol Nutr Food Res       Date:  2014-05-15       Impact factor: 5.914

7.  Iron metabolism and the polycystic ovary syndrome.

Authors:  Héctor F Escobar-Morreale
Journal:  Trends Endocrinol Metab       Date:  2012-05-10       Impact factor: 12.015

8.  Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study.

Authors:  Lisa Lindheim; Mina Bashir; Julia Münzker; Christian Trummer; Verena Zachhuber; Bettina Leber; Angela Horvath; Thomas R Pieber; Gregor Gorkiewicz; Vanessa Stadlbauer; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

9.  Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome.

Authors:  Mehri Jamilian; Fatemeh Foroozanfard; Naghmeh Mirhosseini; Elham Kavossian; Esmat Aghadavod; Fereshteh Bahmani; Vahidreza Ostadmohammadi; Mersedeh Kia; Tahereh Eftekhar; Elnaz Ayati; Mostafa Mahdavinia; Zatollah Asemi
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-14       Impact factor: 5.555

10.  Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes.

Authors:  Jiwoon Kim; Chul Woo Ahn; Sungsoon Fang; Hye Sun Lee; Jong Suk Park
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.